Large-scale testing (Phase 3)Study completedNCT05212948What this trial is testingS-268019 for the Prevention of COVID-19Who this might be right forSARS-CoV-2 Shionogi 9,902
Large-scale testing (Phase 3)Study completedNCT04546425What this trial is testing20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy InfantsWho this might be right forPneumococcal Disease Pfizer 1,258
Testing effectiveness (Phase 2)Study completedNCT00137917What this trial is testingImmunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 YrsWho this might be right forInfections, Meningococcal GlaxoSmithKline 478
Early research (Phase 1)Study completedNCT00920517What this trial is testingSafety and Immune Response to Two Doses of rDEN2/4delta30 Dengue VaccineWho this might be right forDengue Fever National Institute of Allergy and Infectious Diseases (NIAID) 25
Post-approval studies (Phase 4)Ended earlyNCT02522975What this trial is testingBiosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)Who this might be right forRenal Anaemia Shenyang Sunshine Pharmaceutical Co., LTD. 16
Early research (Phase 1)Study completedNCT00822757What this trial is testingSafety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)Who this might be right forHealthy Merck Sharp & Dohme LLC 51
Early research (Phase 1)Study completedNCT04816019What this trial is testingIntranasal ChAdOx1 nCOV-19Who this might be right forCoronavirus University of Oxford 42
Early research (Phase 1)Study completedNCT00427167What this trial is testingPhase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria VaccineWho this might be right forMalaria National Institute of Allergy and Infectious Diseases (NIAID) 300
Early research (Phase 1)UnknownNCT06046092What this trial is testingH7HLAII DNA Influenza VaccineWho this might be right forInfluenza APandemic Influenza Oslo University Hospital 27
Early research (Phase 1)Study completedNCT03451422What this trial is testingSafety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus ErythematosusWho this might be right forSystemic Lupus Erythematosus Amgen 35
Large-scale testing (Phase 3)Study completedNCT05546502What this trial is testingSafety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy ChildrenWho this might be right forVaccine ReactionVaccine Adverse Reaction PT Bio Farma 1,050
Large-scale testing (Phase 3)Study completedNCT00263653What this trial is testingSafety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197Who this might be right forHaemophilus Influenzae Type bNeisseria Meningitidis GlaxoSmithKline 297
Large-scale testing (Phase 3)Not Yet RecruitingNCT06973772What this trial is testingTrial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.Who this might be right forDengueChikungunya Butantan Institute 900
Early research (Phase 1)Study completedNCT00197067What this trial is testingEvaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.Who this might be right forMalaria GlaxoSmithKline 200
Large-scale testing (Phase 3)UnknownNCT06494475What this trial is testingGBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of AgeWho this might be right forStreptococcus Agalactiae Infection Minervax ApS 564
Testing effectiveness (Phase 2)Study completedNCT03455309What this trial is testingEvaluation of NDV-3A Vaccine in Preventing S. Aureus ColonizationWho this might be right forStaphylococcus Aureus NovaDigm Therapeutics, Inc. 382
Early research (Phase 1)Ended earlyNCT06162299What this trial is testingA Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002Who this might be right forChronic Hepatitis B Yisheng Biopharma (Singapore) Pte. Ltd. 16
Early research (Phase 1)Study completedNCT06123663What this trial is testingEvaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and OverWho this might be right forTetanus CanSino Biologics Inc. 60
Large-scale testing (Phase 3)Study completedNCT01978093What this trial is testingImmunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of AgeWho this might be right forNeisseria MeningitidisHaemophilus Influenzae Type b GlaxoSmithKline 600
Large-scale testing (Phase 3)Study completedNCT00368316What this trial is testingSafety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in IsraelWho this might be right forShigellosis Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2,799